TY - JOUR T1 - Metabolic Scar Assessment with <sup>18</sup>F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.246413 SP - jnumed.120.246413 AU - yousra Ghzally AU - Hasan Imanli AU - Mark Smith AU - Jagat Mahat AU - Wengen Chen AU - Alejandro Jimenez Restrepo AU - Mariem A. Sawan AU - Mohamed Aboel- Kassem F Abdelmegid AU - Hatem Abd el Rahman Helmy AU - Salwa Demitry AU - Vincent See AU - Stephen Shorofsky AU - Vasken Dilsizian AU - Timm Dickfeld Y1 - 2021/04/01 UR - http://jnm.snmjournals.org/content/early/2021/04/23/jnumed.120.246413.abstract N2 - Background: Functional/molecular imaging characteristics of ischemic ventricular tachycardia (VT) substrate are incompletely understood. Objective: Compare regional 18F-FDG - PET tracer uptake with detailed electroanatomic maps (EAM) in a more extensive series of post-infarction VT patients to define metabolic properties of the VT substrate/successful ablation sites. Methods: 3D metabolic left ventricular (LV) reconstructions were created from perfusion-normalized 18F-FDG images in consecutive patients undergoing VT ablation. Metabolic defects were defined as severe (&lt;50% uptake) or moderate (50-70% uptake) referenced to the maximal 17-segmental uptake. Color-coded PET scars reconstructions were co-registered with corresponding high-resolution 3D EAM. Results: All 56 patients had ischemic cardiomyopathy (EF=29±12%). Severe PET defect (&lt;50%) was larger than EAM voltage scar (&lt;0.5mV) with 63.0±48.4cm² vs. 13.8±33.1cm² (p&lt;0.001). Similarly, moderate/severe PET defect (‎≤‎70%) was larger than areas with abnormal voltage (≤1.5mV) measuring 105.1±67.2cm² vs. 56.2±62.6cm² (p&lt;0.001). Analysis of bipolar voltage (n = 23,389 mapping-points) showed decreased voltage among PET &lt;50% (n = 10,364; 0.5±0.3mV) to PET 50-70% (n = 5,243; 1.5±0.9mV, p&lt;0.01) with normal voltage among PET normal areas &gt;70% (n = 7,782, 3.2±1.3mV, p&lt;0.001). Eighty-eight percent of VT channel/exit sites (n = 44) were metabolically abnormal (PET &lt;50%: 78%; PET 50-70%: 10%), while 12% (n = 6) were in metabolically normal areas (PET&gt;70%). Metabolic channels (n = 26) existed in 45% (n = 25) of patients with average length/width of 17.6±12.5mm/10.3±4.2mm. Metabolic channels were oriented apex/base (86%) predominantly, harboring VT channel/exit sites in 31%. Metabolic Rapid Transition Areas (RTA: &gt;50% change of 18F-FDG tracer uptake/15mm) were detected in 59% (n = 33) co-localizing to VT channels/exit sites (15%) or its proximity (85%, 12.8±8.5mm). Metabolism-voltage mismatches (MVM) with PET&lt;50%/voltage&gt;1.5mV) were seen in 21% (n = 12) harboring VT channel/exit sites in 41% of patients. Conclusion: Abnormal 18F-FDG uptake categories can be detected using incremental 3D step-up reconstructions. They predicted decreasing bipolar voltages and VT channel/exit sites in ~90%. Additionally, functional imaging allowed detecting novel molecular tissue characteristics within the ischemic VT substrate such as metabolic channels, RTA, and MVM demonstrating intra-substrate heterogeneity and providing possible targets for imaging-guided ablation. ER -